Sen. Alexander Wants To ‘Start From Scratch’ In Regulating Lab-Developed Tests
Executive Summary
Senate HELP Committee Chair Lamar Alexander, R-Tenn., suggested he would prefer to “start from scratch” in developing appropriate regulatory controls for laboratory-developed tests, despite a proposed regulatory framework for US FDA for the tests that was more than a decade in the making. That triggered some debate at a Sept. 20 committee hearing.
You may also be interested in...
FDA Puts Lab-Developed Test Oversight Plans On Hold
After years of wrangling over lab-developed test regulations with laboratory lobbyists, FDA has put its plans to finalize a guidance that lays out its oversight framework for LDTs on hold as a new Congress and a new deregulation-focused president-elect is set to take the helm.
FDA's New Cross-Cutting Oncology Center Gets Pazdur As Lead
FDA's oncology drug guru Richard Pazdur will be heading a new cancer regulatory center aimed at bringing device, drug and biologics regulators together to support new innovations.
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
CMS Deputy Administrator for Innovation and Quality Patrick Conway and FDA Device Center Director Jeffrey Shuren told a House subcommittee that legislators’ efforts to replace FDA’s proposed laboratory-developed test framework would lead to duplicative, time-consuming, expensive regulation, and could only result in ineffective and delayed diagnostics that might harm patients.